Evidence map›Paper›PMID 42764924›Full record

ReviewActa pharmaceutica Sinica. B2026

The polymeric nanovectors landscape for cancer immunotherapies towards advanced therapy medicinal products (ATMPs).

Ilaria Elena Palamà, Alessandra Invidia, Claudia De Stradis, Gabriella Leccese, Clara Baldari, Barbara Cortese, Clara Guido, Andrea Giglio, Concetta Quintarelli, Biagio De Angelis and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ilaria Elena PalamàInstitute of Nanotechnology (NANOTEC)-National Research Council (CNR), c/o Campus Ecotekne, Lecce 73100, Italy.
Alessandra InvidiaInstitute of Nanotechnology (NANOTEC)-National Research Council (CNR), c/o Campus Ecotekne, Lecce 73100, Italy.
Claudia De StradisDepartment of Mathematics and Physics "Ennio De Giorgi", University of Salento, c/o Campus Ecotekne, Lecce 73100, Italy.
Gabriella LecceseInstitute of Nanotechnology (NANOTEC)-National Research Council (CNR), c/o Campus Ecotekne, Lecce 73100, Italy.
Clara BaldariDepartment of Experimental Medicine, University of Salento, c/o Campus Ecotekne, Lecce 73100, Italy.
Barbara CorteseTecnomed Puglia - Tecnopolo per la medicina di precisione (Biotech Lecce Hub), c/o Campus Ecotekne, Lecce 73100, Italy.
Clara GuidoInstitute of Nanotechnology (NANOTEC)-National Research Council (CNR), c/o Campus Ecotekne, Lecce 73100, Italy.
Andrea GiglioInstitute of Nanotechnology (NANOTEC)-National Research Council (CNR), c/o Campus Ecotekne, Lecce 73100, Italy.
Concetta QuintarelliDepartment of Clinical Medicine and Surgery, Federico II University of Naples, Naples 80131, Italy.
Biagio De AngelisDepartment of Onco-Haematology and Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome 00165, Italy.
Gabriele MaioranoInstitute of Nanotechnology (NANOTEC)-National Research Council (CNR), c/o Campus Ecotekne, Lecce 73100, Italy.
Franco LocatelliDepartment of Onco-Haematology and Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome 00165, Italy.
Giuseppe GigliInstitute of Nanotechnology (NANOTEC)-National Research Council (CNR), c/o Campus Ecotekne, Lecce 73100, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite major advances in oncology, cancer remains one of the leading causes of mortality worldwide, underscoring the need for more effective and personalized therapeutic solutions. Advanced therapy medicinal products (ATMPs), including gene and cell-based therapies, have emerged as a promising frontier for immune cell engineering in oncology. However, current approaches still face several technical/safety issues, mainly associated with the delivery strategies used and their complex manufacturing processes. In this context, polymeric nanovectors (pNVs) have gained attention as a promising tool for developing efficient therapeutic delivery systems. The possibility of customizing pNVs' composition/physicochemical properties, exploiting natural/synthetic polymers, enables more precise and controlled cargo delivery to immune cells, paving the way for the development of future ATMPs-oriented strategies for cancer immunotherapy. This review highlights the recent advancements in the application of pNVs for the editing of immune cells, focusing on innovative nanotechnology-based strategies to enhance the precision and efficacy of immunotherapy with a particular emphasis on their prospective role in next-generation ATMP development.

Indexed as

ATMPsCancer immunotherapyImmune cells engineeringNanomaterialsNon-viral gene deliveryPersonalized medicinePolymeric nanovectorsTranslational nanomedicine

Identifiers

PMID42764924
PMCPMC13589935

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.